Nikhil Munshi, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses considerations in the treatment of high risk multiple myeloma (MM) from the 1st European Myeloma Network (EMN) Meeting, in Turin, Italy. He covers more agressive therapy options, as well as intergrating our increased knowledge of genomics to improve treatment.
How to treat high-risk mutated myeloma
